UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000034555
Receipt number R000039392
Scientific Title Berberine containing therapy for Helicobacter Pylori treatment among patients with previous failed eradication
Date of disclosure of the study information 2018/10/20
Last modified on 2019/12/29 16:35:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Berberine containing therapy for Helicobacter Pylori treatment among patients with previous failed eradication

Acronym

Berberine containing therapy for patients with previous failed helicobacter pylori eradication

Scientific Title

Berberine containing therapy for Helicobacter Pylori treatment among patients with previous failed eradication

Scientific Title:Acronym

Berberine containing therapy for patients with previous failed helicobacter pylori eradication

Region

Asia(except Japan)


Condition

Condition

H. pylori infection

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the therapy efficacy (eradication rate) and safety between Bismuth Containing Quadruple Therapy (BCQT) and Berberine Containing Therapy (BCQT plus berberine)

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

eradication rate of H. pylori

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Berberine Containing Therapy (Berberine 0.3g tid, Rabeprazole 10mg bid, Bismuth 500mg bid, Amoxicillin 1g bid and Minocycline 1000mg bid) for 14 days

Interventions/Control_2

Bismuth Containing Quadruple Therapy (Rabeprazole 10mg bid, Bismuth 500mg bid, Amoxicillin 1g bid and Minocycline 1000mg bid) for 14 days

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients positive to Rapid Urease Test
Patients positive to 13C Urease Breath Test
Patients verified of Hp infection with pathology
Patients with previous failed H. pylori eradication

Key exclusion criteria

Patients with allergy history of drugs medicated in this trail
Patients with history of hepatic or/and renal dysfunction
Patients with history of operation on upper digestive tract
Patients with alcoholism and drug abuse
Patients in pregnancy or lactation
Patients who ever participated other clinical trials in latest 3 months

Target sample size

90


Research contact person

Name of lead principal investigator

1st name Yu
Middle name
Last name Lan

Organization

Beijing Jishuitan Hospital

Division name

Departement of Gastroenterology

Zip code

100035

Address

No. 31, Xinjiekou East Street, Beijing

TEL

86-10-58398289

Email

lanyu-mail@sohu.com


Public contact

Name of contact person

1st name Xiao-Bei
Middle name
Last name Si

Organization

Beijing Jishuitan Hospital

Division name

Departement of Gastroenterology

Zip code

100035

Address

No. 31, Xinjiekou East Street, Beijing

TEL

86-10-58398289

Homepage URL


Email

sixiaobei2008@126.com


Sponsor or person

Institute

Health bureau of Beijing

Institute

Department

Personal name



Funding Source

Organization

Administration of traditional Chinese medicine of Beijing

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Beijing Jishuitan Hospital

Address

No. 31, Xinjiekou East Street, Beijing

Tel

86-10-58398289

Email

sixiaobei2008@126.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 10 Month 20 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 09 Month 01 Day

Date of IRB

2018 Year 09 Month 10 Day

Anticipated trial start date

2018 Year 09 Month 01 Day

Last follow-up date

2019 Year 12 Month 20 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 10 Month 17 Day

Last modified on

2019 Year 12 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039392


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name